Charles P. Theuer
results with review and afternoon, an our and then financial update recent for update activities. call. second quarter joining on Good business TRACON’s I our you XXXX thank and will begin pipeline
discuss our Brown, and our Chief will the June Financial Following results that three financial Officer six XX, Scott for XXXX. ended months
Finally, we will conclude by taking your questions.
cohort with on given safety randomized ENVA C of data an Yervoy. blinded monitoring than generally I'll double-digit on-study without ENVA than to greater Grade efficacy progress treatment begin the pivotal scans with continue into Patients cohort combination or a events. interim related reviewed more update well assessed X in equally and with ENVASARC the investigator who patients agent rate ongoing of in two committee June least single date ENVA adverse single continued D had In cohort trial. was CT for central our XX review. response by a at demonstrate tolerated C drug objective independent and
decision of and not data. resulted of ENVA costs and This to with in in synergy The trial treatment combination to timeline a in acceleration Yervoy demonstrate has agent enrollment final compared D. cohort ENVA did reduction single when we the terminated ENVASARC therefore
final duration response cohort ENVA the with agent accrual full in including C patients of of and of quarter expect the treatment mid-XXXX. into We XX by fourth single data
be patient weeks with protocol completed minimum ENVA treated the reported XX mandated after and a conducted addition, of DMC evaluations. has a review efficacy of will In XX
as trial futility includes treatment. responses single XX has of threshold DMC cohort ENVASARC already expect been enrolled occur DMC patients to-date. to-date, patients on review XX a achieved expected This to of agent the has ENVA the XXX including based this quarter in We the review C that seen
exceed primary RECIST, is endpoint XX the response nine of primary that blinded the Votrient, X% As an by achieve rate out the FDA Therefore, a UPS in of response level the a independent MFS. response patients objective treatment with indicating of only response study. the rate or the study, on-track at interim for objective of the rate the defines responses response that to by the objective or approved ENVASARC XX.XX% primary objective are reminder, endpoint to statistically satisfies is rate we central time meaningful, review, of double-digit analysis with confirmed refractory endpoint
for Notably, with a liver a warning box drug Votrient fatal black is toxicity.
data potential therefore, in the efficacious Our inhibitors trials on demonstrate goal nine or and strategy UPS MFS, we we the to refractory in we agent is from as to XX% approach determine are Votrient. that ENVASARC, soon checkpoint filing for Based BLA has as a be both more than FDA Furthermore, ENVA. other plan discuss targeting the response to responses. single rate to of safer ENVA
that and These UPS tissue of a have and have of review commercialization that we orphan subtypes important reminder, activity sarcoma ENVASARC. in expedite progressed designation received have Track provide ENVA ENVA. Fast drug one designations lines based might therapy, two of and As in received prior regulatory or in for observed on soft designation on advantages MFS sarcoma
MFS. provide in approval of to data safety designed UPS and refractory ENVA for the is ENVASARC sarcoma efficacy subtypes the and of
chemotherapy included antibody a in X/X for the a strategy a potential the approval triplet trial of Based Eucure clinical Phase expected ENVA sarcoma. have for YHXXX, best-in-class Biopharma began treatment XXXX, that evaluating licensed and a in of on frontline from ENVA CTLA-X and we Yervoy, and doxorubicin frontline also synergy October sarcoma. ENVA YHXXX We between
given designed. from the the and enrollment ENVA available treated trial CTLA-X lack antibody sarcoma as antibody pivotal and between with However, of a MFS, We initiate doxorubicin enrollment Yervoy, trial data of and in of in setting completion end ENVA decided UPS the ENVASARC plan patients into including to frontline and modified synergy subtypes in YHXXX, the now following of ENVA to common trial. observed ENVASARC we have and the originally
this ENVA subtypes with potential as doxorubicin ENVA expected enroll with of to trial that post the of as trial results compare survival doxorubicin with will the assuming positive would expect Phase the agent progression UPS sarcoma be shown approval be to to a a X expect and MFS, require that subtypes the This trial single other the trial FDA ENVA combination doxorubicin. well now ENVA, survival goal approval The therapy respond patients potential and respond sarcoma determine pivotal endpoint. with We and in trial randomized to demonstrate as will free a to we ENVASARC will of to to and best accelerated of modified doxorubicin, benefit.
the UPS expected FDA We from expected ENVA expect of revenues parity to It time refractory MFS. not with peak submission in of the frontline anticipated a discuss the million is pre-BLA data design ENVASARC potential ENVA fund forecasted annual to potential refractory sarcoma. for approval sarcoma meeting understand important and ENVA pricing our at the is approval of to trial of $XXX accelerated of in sales the in solely review the with
ENVA broadly frontline strategy development create the BLA is to and opportunity by the in sarcoma neoadjuvant adjuvant designed patients supplemental to clinical with settings seeking for benefit Our approvals.
trial in through lung Agreement that the NCI is Development Institute. treatment. enrollment designed in and Cancer The Phase consolidated detect to to The Nine assess endpoint primary the XX open will benefit damage DNA, survival progression in and improvement TRCXXX patients National XX% now one with cell randomized expected sponsoring maintenance for of adding repair an current in of The an from year ongoing trial therapy durvalumab are X PFS the and the TRCXXX stage standard-of-care enroll followed X-arm trial treatment to a U.S. assessing will to XX%. chemoradiation. TRCXXX XXXX. We turn cisplatin supported is combination inhibitor, non-squamous, radiation sites non-small with and pemetrexed, of results trial at is final is Research in Cooperative the are three, by free the cancer
costs the other aggregate legal TRACON. awarded the in million. $X award million $XX amount Next, certain TJXXXX entitled our I to to and declared for will an TRACON I-Mab. provide update also the the and approximately findings, arbitration were TRACON April from which collection our rendered tribunal ruled we award in trial and that on complete, XX, of tribunal of favor Among On an to fees claims informed
in XXXX. In April. collected collected we collected in International million July, Commerce $X.X Chamber time. the deferred as due. is currently of planned of firm net TRACON which used administered to fees remains the the award trust full, I-Mab million satisfaction first $X.X the The $XX arbitration was amount as An and fund million company's to amount of to the in our predicated is proceeds firm of are Award $XX.X expected repay account litigation to-date client of in facility from of additional into disbursement by financing the announced operations legal of to half a discussions the success-based at this of on law million our
a later this or disbursement of discussions, all is that expected portion amount year. these Following of
runway CRO-independent our development us most leveraging one extend further to we form believe featuring platform development product of efficient non-dilutive as that expect capital the clinical our to positions We organizations.
$XX,XXX per As burdened than of ENVASARC CRO may are patient. per $XXX,XXX be our per dosing if favorably trial the order compares that is patients patient considered. less an efficiency, in even with typical estimates our expensive change example, fully more for patient costs This charges bid
we significantly forms. trial expediting In the approval by amendments addition, and duration by believe managing protocol filings all regulatory consent shortened we internally,
response emphasized through the criteria also experienced monitors We accurate with are a reporting. reliable data relevant use of to team ensure who highly quality of site oncology
of development of our from have to trials drug platform collaborated been with product the capital partners attributes us and who run infusions their basis Johnson for have Johnson, like candidates. These
is one focus companies current work Our ways. to two of in with
company their trials. lower but generate First, our plan costs, to anticipated and to teach a who a still to an pipeline multiple by substantial CRO two, operational with capabilities for profit replacing a TRACON, conduct to emerging
pay our CRO. the end This the conduct offering otherwise cost management, for independent will platform of to a is Leveraging company. may data to priority trial development what enable advanced at product to capital platform non-dilutive than CRO our year a reporting top management, trials that efficient our safety collaborator clinical and of would cost they of one-third include for generate of this less
press platform. our reiterate, let please and capital to CRO-independent of this that expect release the development end In generate regard, we note non-dilutive year by leveraging corrected before product me
an At update this financials. our provide will on time, Scott
